Photo from archive.org
The PD-1 inhibitor pembrolizumab may be an effective adjuvant therapy for patients with stage III melanoma. In a clinical trial, patients who received the drug had a 12-month recurrence-free survival… Click to show full abstract
The PD-1 inhibitor pembrolizumab may be an effective adjuvant therapy for patients with stage III melanoma. In a clinical trial, patients who received the drug had a 12-month recurrence-free survival rate of 75.4%, compared with 61% for patients who received a placebo.
Keywords:
prolongs rfs;
therapy melanoma;
melanoma prolongs;
therapy;
adjuvant therapy
Journal Title: Cancer discovery
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer discovery
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!